Protective effects of chlorogenic acid on acute hepatotoxicity induced by lipopolysaccharide in mice.
OBJECTIVE
To investigate the potential protective effects of chlorogenic acid (CGA) on acute liver injury caused by lipopolysaccharide (LPS) in mice.


METHODS
C57BL/6J mice were pretreated with CGA (50 mg/kg, intraperitoneally) once per day for 5 days before an overnight LPS challenge (30 mg/kg, intraperitoneally). Severity of liver injury was assessed by histological analysis and determination of serum ALT and AST levels. Expression and activation of key regulators involved in the inflammatory response were determined, respectively, by real-time RT-PCR and western blotting.


RESULTS
In contrast to the yellow color of the liver in LPS-treated mice, CGA maintained the normal reddish appearance of the liver. Histological analysis indicated that CGA attenuated the infiltration of neutrophil cells and the necrosis of hepatocytes. CGA also decreased the elevated plasma levels of ALT and AST. At the transcriptional level, CGA pretreatment suppressed hepatic mRNA expression of toll-like receptor 4 (TLR4), TNF-alpha and NF-kappaB p65 subunit. In contrast, mRNA level of the transcriptional coactivator PGC-1alpha was restored by CGA. Finally, CGA reduced the phosphorylation of NF-kappaB p65 subunit in the liver.


CONCLUSIONS
Our data suggest that CGA has remarkable hepatoprotective effects on LPS-induced liver injury and that the possible mechanism is related to its anti-inflammatory action.
Xu
Yuexin
Y
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, Nanjing Normal University, Nanjing 210046, China.
Chen
Jingwen
J
Yu
Xiao
X
Tao
Weiwei
W
Jiang
Fengrong
F
Yin
Zhimin
Z
Liu
Chang
C
D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology; D002726:Chlorogenic Acid / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008070:Lipopolysaccharides / Q000378:metabolism / Q000633:toxicity*; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D015394:Molecular Structure; D051996:Transcription Factor RelA / Q000378:metabolism
D008070:Lipopolysaccharides; C498144:Rela protein, mouse; D051996:Transcription Factor RelA; D002726:Chlorogenic Acid
Annu Rev Immunol. 1994;12:141-79
8011280
Infect Immun. 2002 Jul;70(7):3433-42
12065483
Int Immunopharmacol. 2009 Aug;9(9):1042-8
19393773
Biochem Pharmacol. 1989 Feb 15;38(4):627-31
2465008
J Nutr Biochem. 2002 Dec;13(12):717-726
12550056
J Biol Chem. 2001 Jun 15;276(24):21129-35
11274165
Biochim Biophys Acta. 1997 Jun 6;1335(3):335-42
9202196
Mol Cell Biol. 1996 Apr;16(4):1295-304
8657102
Genes Dev. 1995 Nov 15;9(22):2723-35
7590248
Food Chem Toxicol. 2000 May;38(5):467-71
10762733
Hepatology. 1990 Nov;12(5):1187-91
2227817
Cell Metab. 2005 Jun;1(6):361-70
16054085
Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112
16447287
N Engl J Med. 2003 Jan 9;348(2):138-50
12519925
Oncogene. 1999 Nov 22;18(49):6853-66
10602461
Infect Immun. 2002 Jan;70(1):192-8
11748182
J Endotoxin Res. 2000;6(6):453-7
11521070
Am J Physiol Gastrointest Liver Physiol. 2009 Jan;296(1):G45-54
18948440
Hepatology. 2001 Jun;33(6):1441-50
11391533
Nucleic Acids Res. 2006 Feb 25;34(4):1216-23
16500892
Nature. 2002 Dec 19-26;420(6917):885-91
12490963
J Cell Mol Med. 2009 Sep;13(9B):3370-9
19243473
Cell. 2002 Apr;109 Suppl:S81-96
11983155
Toxicol Sci. 2002 Feb;65(2):166-76
11812920
Biol Pharm Bull. 2006 Nov;29(11):2236-40
17077520
Infect Immun. 1996 Mar;64(3):734-8
8641774
J Biol Chem. 2005 Jul 29;280(30):27888-95
15944151
Immunopharmacol Immunotoxicol. 2002 Feb;24(1):113-9
12022439
Shock. 2000 Feb;13(2):110-6
10670840
Immunity. 1999 Oct;11(4):443-51
10549626
Biochemistry (Mosc). 2004 Jan;69(1):70-4
14972021
Curr Opin Immunol. 1999 Feb;11(1):19-22
10047547
Biochem Pharmacol. 2002 Sep;64(5-6):963-70
12213593